## 1 

### Writing Within the Regulated Environment 法规环境下的写作

As far as most regulatory bodies are concerned, if you didn’t write it down, it didn’t happen. Working in the pharmaceutical, medical device, or biologic milieu is tantamount to journal keeping. In fact, “Write it down” sums up what it takes to get the job done properly. Successful operations require a working union of the day-to-day activities that keep the wheels of the business turning and the documentation that affirms those activities.

对大多数监管机构而言，没有记录下来的事情就认为没有发生。在制药，医疗器械或生物环境中工作可等同于保留记录本。事实上，“写下来”概括了如何才能把工作做好。 成功的运营需要将日常活动紧密结合在一起，以保持业务运转，并提供证明这些活动的文件。

Documents show the framework of a company’s varied activities. When the development process for one product is winding down, for example, and a submission is forthcoming, development processes for other products may be in various stages of development, from discovery through final testing in clinical trials and launch. Concurrently, other company products may be in various stages of scale-up or production. For each product in each phase of development or production, there must be a written history that shows control of all activities related to that product. Thus, the answer to “What did the company do in March (or on Tuesday) in the production of acetaminophen?” should be easily available in the records the company keeps.

文件展示了公司各种活动的框架。例如，当一种产品的开发过程快要结束并且即将提交注册时，其他产品的可能处于从发现到临床试验的最终测试再到最终上市的不同开发阶段。 同时，其他公司产品可能处于放大或生产的不同。 对于在开发或生产的每个阶段中的每个产品，都必须有书面的历史记录，以证明对与该产品相关的所有受控活动。 因此，“公司在三月（或星期二）对乙酰氨基酚的生产中做了什么”这个问题的答案应该在公司保存的记录中很容易找到。

The sheer volume of documentation that takes place makes writing well a critical skill, one that is essential for success. It is also true that writing is intimidating for many people. Perhaps because writing is so closely scrutinized, people are loath to commit their words to paper. If writing is on your list of job responsibilities, there are some avenues you can take to make the task less formidable. The first is gaining an understanding of why you are writing and how that writing works in conjunction with other documentation. The next is obtaining the tools you need to deliver clear and complete messages that are grammatically correct and consistent. Acquiring the requisite tools is what this book is all about.

大量的文档使写作成为一项至关重要的技能，这对成功至关重要。 确实，写作对许多人来说是令人生畏的。 也许是因为对写作进行了如此严格的审查，所以人们不愿将自己的文字写在纸上。 如果您的工作职责中包括写作，那么您可以采取一些方法来减轻任务的艰巨性。 首先是要了解为什么要写作以及该写作如何与其他文档一起工作。 接下来是获得传递语法正确且一致的清晰完整消息所需的工具。 本书所涉及的就是获得必要的工具。

### Writing for Compliance with Binding Regulations 遵守约束性法规的写作

Why does writing play such an integral part in companies that develop, manufacture, and market therapeutic products? The answer lies largely with the regulatory forces that drive the healthcare industry in the United States and abroad.

为什么写作在开发，制造和销售治疗产品的公司中起着不可或缺的作用？ 答案是很大程度上取决于驱动美国和国外医疗保健行业的监管力量。

The regulations state what companies must do. Their documentation tells how they do it and what the outcomes are. In a pharmaceutical company, for instance, documentation is the proof that a company’s activities meet the regulatory demands of Title 21 of the Code of Federal Regulations Part 211, Good Manufacturing Practices for Finished Pharmaceuticals. In this environment, documents delineate such diverse activities as facility and equipment qualification, cleaning, and maintenance; control of materials, from incoming components to finished goods; validation of manufacturing processes; sampling and testing activities; nonconformance and out-of-specification (OOS) investigations; and employee training. They provide the “how-to” for auditing vendors and contractors, handling complaints and recalls, and conducting annual product reviews. In short, documents substantiate that a company has complete control of all of its activities in compliance with the regulations.

法规规定了公司必须做什么。 他们的文档告诉他们如何做以及结果如何。 例如，证明一家制药公司的活动符合《联邦法规法典》主题21第211部分“药品良好生产规范”法规要求的证据就是文件。 在这种环境下，文件描述了各种活动，例如设施和设备的确认、清洁和维护、 从进料到成品的物料控制、生产工艺验证、取样和检验活动、 不合格和超限（OOS）调查以及员工培训等。 它们为审核供应商和承包商，处理投诉和召回以及进行年度产品回顾提供了“方法”。 简而言之，文件证明公司完成了遵守法规所需的受控活动。

In the United States (US), 21 CFR Part 820 Quality System Regulation delineates the Good Manufacturing Practices (GMPs) for medical devices and Part 606 Good Manufacturing Practice for Blood and Blood Components delineates them for biologics. Most countries have similar regulations to ensure the safety and efficacy of products. Canada, for instance has the Canadian Health Protectorate Branch (CHPB), Ireland has the Irish Medicines Board (IMB), the United Kingdom has the Committee on Safety and Medicine (CSM), Australia has the Australian Code of GMP for Therapeutic Goods, and Japan has the Ministry of Health and Welfare (MHW). In numerous other countries, regulations come from the Ministry of Health (MOH).

在美国，21 CFR第820部分《质量体系法规》描述了医疗器械的良好制造规范（GMP），第 606部分《血液和血液成分的良好制造规范》则对生物制品进行了阐述。 大多数国家都有类似的规定，以确保产品的安全性和有效性。 例如，加拿大设有加拿大健康保护局（CHPB），爱尔兰设有爱尔兰药品管理局（IMB），英国设有安全和药品委员会（CSM），澳大利亚设有澳大利亚治疗性药品GMP规范，以及 日本设有厚生省（MHW）。 在许多其他国家，法规来自卫生部（MOH）。

While countries have their own regulatory authorities for ensuring safety and efficacy in drugs, devices, and biologics, they are also recognizing that internationally acceptable standards can help put products into world markets. Companies conducting clinical trials worldwide embrace the International Conference for Harmonisation (ICH) Guidelines, established in 1964 and revised in 1975 and 1986. These guidelines, which have their origins in the Declaration of Helsinki, present an international standard for designing, conducting, recording, and reporting clinical trials in which human subjects are participants. They were developed in consideration of the clinical practices of the European Union (EU), Japan, the United States, Australia, Canada, the Nordic countries, and the World Health Organization.

尽管各国都有自己的监管机构来确保药物，器械和生物制剂的安全性和有效性，但它们也认识到国际上可接受的标准可以帮助将产品推向世界市场。 在全球范围内进行临床试验的公司都采用国际协调会议（ICH）指南，该指南成立于1964年，并于1975年和1986年进行了修订。这些指南起源于《赫尔辛基宣言》，为涉及人类受试者的临床试验的设计，进行，记录， 报告提供了国际标准。 它们的开发考虑了欧盟（EU），日本，美国，澳大利亚，加拿大，北欧国家和世界卫生组织的临床实践。

In Europe, the European Medicines Evaluation Agency represents 15 member nations. The International Organisation for Standardization (ISO) promulgates standards for quality worldwide and offers certification. And Mutual Recognition Agreements (MRAs) between nations also attest to the drive toward uniform, internationally accepted standards for therapeutic products development.

在欧洲，欧洲药品局代表15个成员国。 国际标准化组织（ISO）颁布了全球质量标准并提供认证。 国家之间的相互认可协议（MRA）也证明了国际认可的治疗产品开发标准趋于统一。

One manifestation of this sort of standardization is the Common Technical Document (CTD). Many nations now mandate the CTD as the vehicle for gaining approval to market a drug, biologic, or device. Some countries recommend and will accept the format, but until they change the regulations in place, they do not make it a formal requirement. Until FDA, for instance, makes a revision to 21 CFR Part 314, NDA it won’t be mandatory to submit a New Drug Application (NDA) in the CTD format. The outline for the CTD allows companies to devise one document that they can submit to many countries for product approval. The variable piece is the section on Quality Assurance. (See Chapter Eight for more information about the CTD.)

这种标准化的一种体现是通用技术文档（CTD）。 现在，许多国家/地区要求CTD作为获得批准销售药物，生物制品或设备的工具。 一些国家建议并接受该格式，但是在他们更改现行法规之前，还没有将其作为正式的要求。 例如，在FDA对21 CFR Part 314（NDA）进行修订之前，强制要求以CTD格式提交新药申请（NDA）。 CTD的大纲使公司可以设计一份文件，可以提交给许多国家进行产品批准。 可变部分是“质量保证”部分。 （有关CTD的更多信息，请参见第八章。）

Few, if any, companies are driven by just one set of regulations. A typical US pharmaceutical company may be subject to the regulatory guidelines set forth by the Food and Drug Administration (FDA) in Title 21 CFR Parts 210 and 211 as well as those set forth by the Environmental Protection Agency (EPA), Drug Enforcement Administration (DEA), Occupational Safety and Health Administration (OSHA), the Department of Transportation (DOT), and various other state and federal organizations. If it seeks to manufacture or market a product outside the US, it must look to the binding regulations in targeted countries.

只有很少的公司（如果有的话）仅受一套法规的约束。 典型的美国制药公司可能要遵守美国食品药品管理局（FDA）在21 CFR第210和211部分以及美国环境保护署（EPA），缉毒局（ DEA），职业安全与健康管理局（OSHA），交通部（DOT）以及其他各种州和联邦组织颁布的法规要求。 如果要在美国以外生产或销售产品，则必须遵守目标国家/地区的约束性法规。

Once in place, regulations don’t change all that rapidly. However, it takes about five years for industry standards to develop. Once a regulatory agency issues a regulation, dialog among companies and FDA takes place, and industry “best practices” develop. Consider, for example, 21 CFR Part 11, Electronic Records; Electronic Signatures. This regulation, vague in nature, has generated tremendous discussion, and FDA has issued many guidances as to how the law is to be interpreted. Industry standards are now in place for this regulation, although discussion continues. More recently, the US Department of Public Welfare and Human Services issued 45 CFR Parts 160, 162, and 164 for electronic record keeping of patient records. This regulation bridges into FDA-regulated industries, since developers of therapeutics engaged in clinical trials manage patient data. These regulations, part of the Health Insurance Portability and Accountability Act (HIPAA), are new, and industry standards are developing. However, companies seeking to comply will do well to understand industry standards for Part 11, since the regulations are parallel, even though issued by separate agencies.

法规一旦制定，就不会很快改变。但是（由法规）形成行业标准大约需要5年时间。当监管机构颁布法规后，企业与FDA之间的对话就会展开，行业的“最佳实践”也将逐步完善。例如，21CFR第11部分，电子记录与电子签名，因为其本身含混不清，引起了极大的争论，FDA发布了许多解释应当如何执行该法规的指南。该法规的行业标准已经制定，但争论仍在继续。最近（2005年，本书写作时间），美国公共福利与人类服务部发布了45 CFR 第 160、162和164部分，用于规范保存患者病历的电子记录。该法规一只脚跨进了FDA监管的行业，因为新疗法临床试验的开发人员管理受试者的病历。这些新的法规是《健康保险可移植性和责任法案》（HIPAA）的一部分，相应的行业标准正在制定中。但是，那些寻求遵守（这些法规）的公司将更容易理解第11部分的行业标准，虽然法规由不同部门颁布，但是法规（的内涵）是相似的。

Further, companies must also understand that new regulations don’t supersede existing ones. Predicate rules, those already in place, still apply. Thus, companies complying with 21 CFR Part 11 must continue to follow the regulations that drive their operations. If a medical device manufacturer goes to electronic record keeping, the guidelines for the records themselves reside in 21 CFR Part 820. This is the way most regulations work.

此外，公司还要了解新法规不会取代已有法规。既有规则（那些在原来法规已经存在的规则）仍然适用。因此，遵守21 CFR 11部分的公司必须继续遵守推动其运营的法规，如果医疗设备制造商要进行电子记录保存，则记录本身的准则位于21 CFR 820部分中。这是大多数法规的工作方式。

Managing the regulatory maze is not easy. Yet keeping abreast of the regulations and remaining compliant makes good business sense. Monthly publications for industry, available by subscription, detail issues in the industry and governmental rulings. Industry forums, conferences, and courses offered by professional training organizations offer opportunities to remain current. It’s not enough to adhere to the regulations. Companies need to understand the direction in which compliance is moving and keep in step. The last thing a company needs is a routine investigation that discovers nonstandard practices. The result will be a discrepancy observation, citing what needs to be fixed. It’s always better to have everything in place, with documented proof that it is, rather than to scramble to fix what the company has been cited for—this slows productivity and makes poor business sense. One thing is abundantly clear: Documentation will continue to be critical to every facet of doing business within this highly regulated environment.

管理法规迷宫并不容易。 但是，与法规保持一致并保持合规性具有良好的商业意义。可通过订阅获得的行业月刊，详细列出了行业和政府裁决中的问题。专业培训组织提供的行业论坛，会议和课程提供了保持最新状态的机会。 仅仅遵守法规是不够的。公司需要了解合规性发展的方向，并与时俱进。 公司需要做的最后一件事是发现不规范做法的例行调查。 结果将是差异性观察，并指出了需要解决的问题。 最好将所有内容都放在适当的位置，并附上有据可查的证据，而不是为了确定公司被引用的内容而争先恐后地进行，这会降低生产率并降低商业意义。 有一件事很清楚：在这个受到严格监管的环境中，文档对于开展业务的各个方面仍然至关重要。

***

#### `Regulatory Evolution in the United States美国的法规演变 `

`Laws governing therapeutic product development and marketing have evolved over time with specific laws marking milestones over a period of 100-plus years. The first US federal regulation dates back to 1884 when American soldiers died after ingesting adulterated quinine. As a result of these deaths, the government passed the Drug Importation Act, which required customs inspections on drugs coming from overseas. Then in 1901, The Biologic Control Act became law after 13 children died from a contaminated antitoxin for diphtheria. This act gave the government regulatory power over antitoxin and vaccine development. Shortly after, in 1906, the government passed the Food and Drugs Act to authorize the government to monitor food purity and safety of medicines. `

`管理治疗产品开发和销售的法律在过去的100年间随着时间不断发展，里程碑就是那些特定的法律。美国第一个联邦法规可以追溯到1884年，当时美国士兵摄取了掺假的奎宁后死亡。因为这些士兵的死亡，政府通过了《药品进口法案》，要求海关对那些来自海外的药品进行检查。1901年，因为13名儿童死于受污染的白喉抗毒素，《生物制品控制法案》成为法律。该法案赋予了政府对抗毒素和疫苗开发的监管权。不久之后，1906年，政府通过了《食品与药品法案》，授权政府对食品的纯度和药品安全性进行监管。`

`In 1931, the Food and Drugs Act was renamed the Food and Drug Administration. Several other events were significant in developing binding regulations designed to protect humans and animals. The 1932 Tuskegee Study of Untreated Syphilis in the Negro Male, conducted under the auspices of the US Public Health Service, deprived infected men of effective treatment so as not to interrupt the project. Then in 1937, 107 people died after taking “elixir of sulfanilamide,” which turned out to be an antifreeze solution. FDA removed the product from the market, not because it caused fatalities, but because it was mislabeled. In 1938, the government passed the Food, Drug, and Cosmetics Act. This Act expanded the role of FDA to control of cosmetics and devices.`

`1931年，《食品与药品法案》更名为《食品与药品管理法》。其他几项重大事件对于制定旨在保护人类和动物的约束性法规也很重要。1932年，在美国公共卫生局主持下的塔斯基吉梅毒研究为了避免项目中断，剥夺了黑人受感染男性的有效治疗。（注：塔斯基吉梅毒实验是美国公共卫生局性病部门在1932年至1972年间于阿拉巴马州与当地历史悠久的黑人大学塔斯基吉大学合作，对近399名非洲裔男性梅毒患者及201名健康非洲裔男性所进行的一系列人体试验。这些实验参与者皆为生活贫困的阿拉巴马州梅肯县佃农。该实验以提供免费医疗、餐点、丧葬保险以吸引居民参与实验，也以此目的募集基金。但在经济大萧条导致经费补助中断后，参与者将不再有机会接受任何医学治疗，但研究者仍在未告知参与者的情况下继续进行实验。自始至终，研究者都不曾对罹患梅毒的参与者告知罹患梅毒的实情，而是宣称患者接受的治疗是为了医治败血症，也从不曾施予参与者有效的治疗方式。实验开始之初，梅毒还是无药可医的绝症；但1943年，医学界发现青霉素可有效医治梅毒后，研究人员为了使该实验继续进行，故意不对患者施以有效治疗手段，甚至企图阻止参与实验的梅毒患者接受有效治疗。此实验一直持续在相关领域期刊发表研究报告，少数学者呼吁终止该实验，却遭无视；一直到1972年，实验知情人向大众媒体揭发，该实验才终止。美国政府则迟至1997年才对受害者作出赔偿及公开道歉。）1937年，又有107人因服用磺胺醑剂死亡，最后归结原因为防冻液。（注：即二甘醇，有甜味，可与水混溶，工业上可用作防冻剂。在本次事件中，药剂师哈罗德·沃特金斯用工业溶剂二甘醇代替乙醇和糖，造成358人肾衰竭、107人中毒死亡，其中大部分是儿童。美国联邦法院决定对制药公司罚款26000美元，药剂师沃特金斯在内疚和绝望中自杀。）FDA从市场上移除了该产品，不是因为它造成的死亡，而是因为它的标签错误。（注：根据当时的法律，FDA只能如此处理）1938年，政府通过了《食品、药品和化妆品法案》，该法案将FDA的监管权限扩展到了化妆品和医疗器械。`

`It was during World War II, however, that experiments were done in large scale on unconsenting humans. The Nuremberg War Crime Trials brought these atrocities to light, and the result was the Nuremberg Code, which cited ten standards for ethical human research. `

`然而，在二战期间进行了大量未经同意的人体试验。战后，纽伦堡战争罪行审判揭露了这些暴行，并最终形成纽伦堡法典，里面列举了人体研究的十大道德标准。`

`A wake-up call for even better monitoring came in 1962, when thousands of babies were born with defects, the result of their mothers taking thalidomide while pregnant. The drug had never been approved for marketing in the US, but was undergoing research in American women. Of these women, nine gave birth to defective infants. This event induced FDA to require notification of investigational use of drugs, which up until this time, had not been required. The result was the Kefauver-Harris Amendment to the Food, Drug, and Cosmetic Act. `

`1962年，人们开始呼吁进行更有力的监管，当时成千上万的婴儿出生时有缺陷，这是由于母亲在怀孕期间服用了沙利度胺。沙利度胺从未在美国获准上市，但是当时在美国女性中正进行临床试验。这些（参加试验的）女性，共有9个生下了有缺陷的婴儿。这次事件导致FDA要求通知药物的研究用途，在当时还没有该项要求。沙利度胺事件最终促成了《科夫沃-哈里斯修正案》的出台。`

`At about the same time, President John F. Kennedy announced the Consumer Bill of Rights in a message to Congress. This Bill of Rights said that people have the right to safety, the right to be informed, the right to choose, and the right to be heard. In the same period, in 1964, the World Medical Association issued the Declaration of Helsinki, and physicians were tasked with embracing this statement: “The health of my patients will be my first consideration.” The declaration has been amended four times, and the Code of Federal Regulations (CFR) has incorporated the basic elements. `

`大约在同一时间，约翰·肯尼迪总统（John F. Kennedy）在致国会的消息中宣布了《消费者权益法案》。这份权利法案称，人们有权享有安全权，知情权，选择权和发表意见的权利。在同一时期，世界医师协会于1964年发布《赫尔辛基宣言》，医生被要求接受这样的声明：我将患者的健康作为我的首要考虑。《宣言》已经修订了四次，联邦法规（CFR）已经包含了其基本要素`

`In 1972, the National Institutes of Health transferred the regulation of biologics to FDA. This was followed by the National Research Act, which created the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. Additional legislation has continued to promote ethical treatment of healthcare recipients. In 1978, FDA published the current Good Manufacturing Practices, 21 CFR Parts 210 and 211. `

`1972年，国立卫生研究院（NIH）将生物制品的监管移交给了FDA。随之而来的是《国家研究法》，该法设立了国家人类医学生物医学和行为研究保护委员会。进一步的立法持续促进医疗保健接受者的道德待遇。1978年，FDA发布了现行的《良好生产规范》（cGMP），21 CFR 210和211部分。`

`In 1988, the FDA became an agency of the Department of Health and Human Services. Since that time, the ICH has been formed. A significant ICH goal is to maintain safeguards on quality, safety, efficacy, and regulatory obligation for the protection of the public. The 1997 Food and Drug Administration Modernization Act reauthorized the Prescription Drug User Fee Act of 1992 and instituted reforms in agency practices. In 1996, medical devices became subject to Quality System Regulation (QSR) 21 CFR Part 820. In 1996, as well, the Department of Health and Human Services enacted HIPAA into law. This provided the forward momentum for broad changes in the healthcare industry, but the specifics of the regulation were still being written. Shortly thereafter, in 1997, 21 CFR Part 11 Electronic Records; Electronic Signatures was enacted. `

`1988年，FDA成为卫生与公共服务部的下属机构。那时，ICH已经成立。 它的一个重要目标就是保护公众，维护（药品）质量，安全性，功效和监管义务方面的保障措施。1997年，《FDA现代化法案》重新授权了1992年的《处方药使用者付费法》（PDUFA，该法案有一项“日落条款”，如果国会不重新授权，它将在五年后失效。每五年必须重新商讨该条款，其中可能包括讨论该机构是否需要更多资金、FDA 是否履行了其承诺、行业是否应该持有不同的期望，或者FDA 是否需要以不同的方式传达其期望。）并改革FDA。1996年，医疗器械成为质量体系法规（QSR）21 CFR 820部分的主体。1996年，卫生与公共服务部也将HIPAA颁布为法律。 这为医疗保健行业的广泛变革提供了前进的动力，但该法规的具体内容仍在撰写中（本书成稿时）。此后不久，在1997年21 CFR 11部分“电子记录与电子签名”发布。`

`The government does not issue laws without forethought. The Office of the Federal Register issues the Federal Register (FR), a weekly disclosure publication that informs citizens of their rights and obligations by providing access to the official text of approved regulations and descriptions of federal organizations, programs, and activities. It also publishes texts of proposed regulations and changes to existing regulations. This gives industry the opportunity to react and share dialog with the government agency that has ownership of the proposal. Reviewers can comment on content and wording, the date the regulation goes into effect, and the penalties for noncompliance. Comments are reviewed in a government forum, and the final text becomes the “final rule.”`

`政府不会在没有深思熟虑的情况下颁布法律。联邦纪事办公室发布《联邦纪事》（FR），这是每周公开的出版物，通过提供已批准法规的正式文本以及对联邦组织，计划和活动的描述，向公民通报其权利和义务。它还公布的法规提案文本及对现行法规的修改。这使业界有机会与拥有提案所有权的政府机构进行反馈并与他们对话。审阅者可以评论内容和措辞，法规生效的日期以及对违规行为的处罚。评论在政府论坛中进行审核，最终文本成为“最终规则”。`

` Once enacted, laws are published in the CFR, issued annually on April 1. Laws are enforceable by the respective divisions within the Department of Health and Human Services. It’s important to note, however, that once a final rule appears in the FR, companies are responsible for instituting compliance. Thus, keeping abreast of the regulations requires constant vigilance. ` 

`（提案）一旦成为法律，将在每年4月1日出版的CFR中发布，具体由卫生和公共服务部内的各个部门执行。不过，请务必注意，一旦最终规则出现在FR中，公司就有责任建立合规性。因此，与法规保持同步需要时刻保持关注。`

`The CFR contains regulations of specific government departments and agencies. The CFR has 50 “Titles,” each assigned to a different unit of government. Title 21, Food and Drugs, contains regulations mandated by FDA. Title 45, Public Welfare, falls under the auspices of the National Institutes of Health (NIH). Each title of the CFR is then divided into chapters, and each chapter is divided into parts and subparts. `

`CFR包含特定政府部门和机构的法规。CFR有50个“主题”，每个主题都分配给不同的政府部门。章节21，食品和药品，包含由FDA执行的法规。章节45，公众福利，由国立卫生研究院（NIH）主持。CFR的每个主题分为若干章节，并将每一章节分为多个部分和子部分`

`Remember, too, that as new regulations are enacted, they do not supersede existing regulations unless the government has rescinded them. New regulations in essence become adjuncts to the ones already in place. Companies must adhere to predicate rules and remain vigilant about industry best practices for compliance.`

`还要记住，新法规颁布后，除非政府取消了旧法规，否则它们不会取代现有法规。从本质上讲，新法规成为现有法规的补充。 公司必须遵守既有规则，并对行业最佳实践时刻保持关注。`

***

